Vials containing the Janssen Coronavirus Disease (COVID-19) vaccine from Johnson & Johnson.
Johnson & Johnson via Reuters
100 cases of a rare but serious neurological disorder have been reported following the Johnson & Johnson Covid-19 vaccination, but preliminary data suggests the benefits of the vaccinations still outweigh the risks, the Centers for Disease Control and Prevention shared on Thursday with.
According to slides released the Thursday before a presentation to the CDCs, there were 8.1 cases of Guillain-Barre syndrome per 1 million doses, which is higher than expected in the general population and almost eight times what was seen in the recordings of Pfizer and Moderna Advisory Committee on Vaccination Practices. Guillain-Barre is a rare neurological disorder in which the body’s immune system mistakenly attacks part of the nervous system.
The data does not show a similar pattern with the Pfizer or Moderna vaccine, the US agency said. By comparison, there was about 1 case of Guillain-Barre per million doses in people who received either of the two-dose mRNA vaccines, according to the agency.
The additional data comes a little over a week after the Food and Drug Administration announced a new warning for J&J inclusion after preliminary reports of Guillain-Barre syndrome were found in some J&J recipients.
Of the 100 cases, 95 people were seriously ill, according to the CDC. One person died.
This is a developing story. Please check again for updates.
